Affandi Khairunisa Ahmad, Tizen Nur Maya Sabrina, Mustangin Muaatamarulain, Zin Reena Rahayu MdReena Rahayu Md
Department of Pathology, Universiti Kebangsaan Malaysia Medical Centre, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
J Pathol Transl Med. 2018 Sep;52(5):283-289. doi: 10.4132/jptm.2018.08.14. Epub 2018 Aug 31.
Lung cancer is the third most common cancer worldwide. With major advances in the molecular testing of lung cancers and the introduction of targeted therapies, the distinction between adenocarcinoma and squamous cell carcinoma as well as pathologic subtyping has become important. Recent studies showed that p40 is highly specific for squamous and basal cells and is superior to p63 for diagnosing lung squamous cell carcinoma. The aim of this study was to evaluate the use of p40 immunohistochemical stain in the diagnosis of non-small cell lung carcinoma and its potential to replace current p63 antibody as the best immunohistochemical squamous marker.
Seventy formalin-fixed paraffin-embedded cases previously diagnosed as primary lung squamous cell carcinoma (n = 35) and lung adenocarcinoma (n = 35) from January 2008 to December 2016 were retrieved. The results of tumour cell immunoreactivity for p40 and p63 antibodies in lung squamous cell carcinoma and lung adenocarcinoma were compared.
p40 was expressed in 27 cases of lung squamous cell carcinoma (77.1%). All cases of lung adenocarcinoma (35/35, 100%) were negative for p40. p63 expression was positive in 30 cases of lung squamous cell carcinoma (85.7%) and 13 cases of lung adenocarcinoma (37.1%). Reactivity for both p40 and p63 in lung squamous cell carcinoma was strong and diffuse, whereas variable reactivity was observed in lung adenocarcinoma.
p40 is an excellent marker for distinguishing lung squamous cell carcinoma from adenocarcinoma, and p40 expression is equivalent to p63 expression in lung squamous cell carcinoma.
肺癌是全球第三大常见癌症。随着肺癌分子检测的重大进展以及靶向治疗的引入,腺癌和鳞状细胞癌之间的区分以及病理亚型分类变得至关重要。最近的研究表明,p40对鳞状细胞和基底细胞具有高度特异性,在诊断肺鳞状细胞癌方面优于p63。本研究的目的是评估p40免疫组化染色在非小细胞肺癌诊断中的应用及其取代当前p63抗体作为最佳免疫组化鳞状标志物的潜力。
检索2008年1月至2016年12月期间70例先前诊断为原发性肺鳞状细胞癌(n = 35)和肺腺癌(n = 35)的福尔马林固定石蜡包埋病例。比较肺鳞状细胞癌和肺腺癌中肿瘤细胞对p40和p63抗体的免疫反应性结果。
27例肺鳞状细胞癌(77.1%)表达p40。所有肺腺癌病例(35/35,100%)p40均为阴性。30例肺鳞状细胞癌(85.7%)和13例肺腺癌(37.1%)p63表达呈阳性。肺鳞状细胞癌中p40和p63的反应性均强烈且弥漫,而在肺腺癌中观察到不同的反应性。
p40是区分肺鳞状细胞癌和腺癌的优秀标志物,且在肺鳞状细胞癌中p40表达等同于p63表达。